Senores Pharmaceuticals Ltd. (SPL) has appointed Manohar Lalge as President – Research and Development.

With over 20 years of expertise in pharmaceutical formulation, Lalge has successfully developed and filed more than 100 products for regulated markets across diverse solid oral dosage forms.  His professional journey includes roles at leading healthcare and pharma companies such as Zydus Cadila, Torrent Pharmaceuticals, Ajanta Pharma, Jubilant Lifesciences, and Wockhardt Research Centre.

Senores believes that Lalge’s deep technical expertise and strategic vision will further strengthen its commitment to innovation, quality, and delivering advanced healthcare solutions worldwide.  

Earlier this month, the company also appointed Sanjay Moralwar as Head – IT, strengthening its leadership team.

Senores is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets. Its current portfolio includes 70 Abbreviated New Drug Applications (ANDAs) and 27 CMO/CDMO commercial products permitted for distribution in the USA.

The company also develops and manufactures complex generics certified by global food and drug authorities and currently delivers generic drugs to more than 40 countries. Senores has approvals from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral, Ahmedabad, India, with over 308 product registrations and 719 product applications for emerging markets. The company also manufactures critical care injectables and Active Pharmaceutical Ingredients (APIs).

Senores operates two formulation manufacturing facilities—one in Atlanta, US, which is USFDA approved and DEA, TAA and  BAA compliant for controlled substances and government supplies, and another in Chhatral, India, approved by WHO-GMP for emerging markets. Additionally, it has two API manufacturing facilities in India, located in Chhatral and Naroda (both near Ahmedabad), and a strong research and development capabilities across three R and D centres (two in India and one in the USA) to drive a differentiated product portfolio.  

Earlier this month, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, the company signed an agreement to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA, Inc.